Stocks Health care IGC
NYSE · Health careIGC Pharma, Inc. (IGC)
IGC Pharma, Inc. reported revenue of $1.3M in fiscal 2025, down 5.5% from a year earlier. It posted a net loss of $7.1M. In fiscal 2025 capital spending exceeded operating cash flow by $4.9M. At June 30, 2026 it held $331K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about IGC Pharma, Inc.
- Net worth
- IGC Pharma, Inc. has a market value (market cap) of $20.6M at the latest share price, and shareholders' equity of $6.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.3M (-5.5% year on year), with a net loss of $7.1M.
- Cash flow
- In fiscal 2025 operations used $4.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- IGC Pharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What IGC Pharma, Inc. does
IGC Pharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker IGC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.3M | -$7.1M | -$0.09 | -$4.9M |
| 2024 | $1.3M | -$13M | -$0.22 | -$5.3M |
| 2023 | $911K | -$11.5M | n/a | -$7.4M |
| 2022 | $397K | -$15M | n/a | -$7.7M |
| 2021 | $898K | -$8.8M | -$0.21 | -$12.3M |
| 2020 | $4.1M | -$7.3M | -$0.19 | -$13.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IGC ranks in Health care
Latest SEC filings
What IGC Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 19% to $265K versus the same quarter last year; diluted EPS -$0.03 versus -$0.02.
- July 14, 2026
- July 6, 2026
- June 8, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 3.9% to $317K versus the same quarter last year; diluted EPS -$0.02 versus -$0.02.
- April 20, 2026
- March 30, 2026Other event 8-K
- March 18, 2026Transition-period annual report 10-KT · period to December 31, 2025
- March 12, 2026
- January 6, 2026
Insider trades
What the people running IGC Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 3 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 25, 2026 | Grimaldi ClaudiaPFO, Director | Gave as a gift | 150,000 | - |
| September 25, 2026 | Mukunda RamCEO, Director | Gave as a gift | 100,000 | - |
| September 25, 2026 | Mukunda RamCEO, Director | Gave as a gift | 100,000 | - |
| June 30, 2026 | Grimaldi ClaudiaPFO, Director | Received as pay | 2,048,378 | $553.1K |
| June 30, 2026 | Mukunda RamCEO, Director | Received as pay | 2,226,475 | $601.1K |
| April 1, 2026 | Grimaldi ClaudiaPFO, Director | Exercised options | 100,000 | - |
| April 1, 2026 | Grimaldi ClaudiaPFO, Director | Exercised options | 138,462 | $36K |
| April 1, 2026 | Moran James PDirector | Exercised options | 80,000 | - |
Who owns IGC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bradbury Strategic Investment Fund A13D, may seek influence | 18.3% | May 21, 2024 |
Largest institutional holders
Insiders
4 insiders reported holding 13,634,392 shares in total, about $2.7M at the last price.
| Holder | Shares |
|---|---|
| Mukunda RamCEO, Director | 7,586,314910,751 held indirectly |
| Grimaldi ClaudiaPFO, Director | 3,271,092 |
| Prins Richard KDirector | 1,541,251 |
| Moran James PDirector | 1,235,735 |
Questions about IGC
What does IGC Pharma, Inc. do?
IGC Pharma, Inc. is a company in the Health care sector, listed on NYSE as IGC. Its shares trade on NYSE under the ticker IGC.
What is IGC Pharma, Inc.'s net worth?
IGC Pharma, Inc. has a market value (market cap) of $20.6M at the latest share price, and shareholders' equity of $6.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is IGC Pharma, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $7.1M on revenue of $1.3M.
How much revenue does IGC Pharma, Inc. make?
In fiscal 2025 IGC Pharma, Inc. reported revenue of $1.3M. That is 5.5% less than a year earlier.
When did IGC Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 29, 2026.
When is IGC Pharma, Inc.'s next earnings report?
IGC Pharma, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IGC with
Follow IGC
Get an email when IGC Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values IGC Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.